IL15 and hepatocellular carcinoma: GPC-3-targeted CAR-T cells have been proven to have good safety and efficacy in the therapy of HCC, and GPC-3-CAR-T cells with the co-expression of IL-15 and IL-21 demonstrated superior cell proliferation and anti-tumor ability [192–194].